## 2026 Preventive Services Reference Guide for Members

In accordance with the Patient Protection and Affordable Care Act of 2010 (PPACA), many preventive services, including screening tests and immunizations, are covered by UPMC Health Plan at no cost to members. Below is a list of services that should be covered without a copayment or coinsurance and without the need to meet your deductible as long as the services are delivered by a network provider and in compliance with the terms of the preventive recommendation. Please be aware that this list may be amended from time to time to comply with federal requirements.

Please note: Routine preventive exams may result in specific diagnoses from your doctor or the need for follow-up care. If you require follow-up care or if you're already being treated for a condition, injury, or illness, services related to such care may not be considered preventive and may result in health care expenses, such as copayments and coinsurance. This is true even if the services are included on the list below. If you have any questions, please call your Health Care Concierge tearn at 1-888-876-2756 (TTY: 711) Monday through Friday from 8 a.m. to 6 p.m.

Under some plans that are "grandfathered" under the PPACA, you may have to pay all or part of the cost of routine preventive services. Please refer to your specific Schedule of Benefits.

## Covered Preventive Services for Adults Ages 18 and Older

#### **EXAMINATION AND COUNSELING**

Clinical indicator	Ages 18-29	Ages 30-39	Ages 40-49	Ages 50-64	Ages 65+						
Blood pressure		A	nnually as part of a physical or well-v	risit.							
Depression	Each visit as appropriate.										
General physical exam	Annually.										
Obesity prevention in midlife members		Annual counseling for midlife members ages 40-60 with normal or overweight body mass index (18-29.9 kg/m²) to maintain weight or limit weight gain. Counseling may include an individualized discussion of healthy eating and physical activity.									
Screen/Counsel/Refer for tobacco use, alcohol misuse, substance use, skin cancer, healthy diet, and/or intimate partner violence	Each visit as appropriate.										
Sexually transmitted infection (STI) prevention counseling			Each visit for high-risk adults.								
Weight loss to prevent obesity-related morbidity and mortality	Offer or refer adults with a body mass index (BMI) of 30 or higher to intensive, multicomponent behavioral interventions,										

#### PREVENTIVE MEASURES

Clinical indicator	Ages 18-29	Ages 30-39	Ages 40-49	Ages 50-64	Ages 65+								
Abdominal aortic aneurysm screening					One-time screening with ultrasonography in men ages 65-75 years who have smoked								
Anxiety screening		Screening intervals based upon clinical judgment.											
Blood pressure monitoring	If blood pre-	If blood pressure numbers are high, additional monitoring with home blood pressure monitoring outside of the doctor's office or clinic to confirm diagnosis of high blood pressure before starting treatment.											
BRCA screening and counseling		One-time genetic assessment for members with a personal or family history of breast, ovarian, tubal, or peritoneal cancer, as recommended by their doctor.  Members with positive screening results should receive genetic counseling and, if indicated after counseling, BRCA testing.											
Breast cancer preventive medications		Risk-reducing medications, such as tamoxifen, raloxifene, or aromatase inhibitors, for members who are at increased risk for breast cancer and at low risk for adverse medication of											
Breast cancer screening		Annually.											
Cervical cancer screening	For members ages 21-29, screening every three years with cervical cytology alone.		For members ages 30-65, screening every three years with cervical cytology alone, every five years with high-risk hum papillomavirus (hrHPV) testing alone, or every five years with hrHPV testing in combination with cytology (cotesting										

1This guide is intended for members with employer sponsored and/or individual Marketplace insurance. It is not intended for members with government sponsored insurance, such as Medicare and Medical Assistance plans.
PSRG 2026

UPMC HEALTH PLAN

## Covered Preventive Services for Adults Ages 18 and Older (cont'd)

## PREVENTIVE MEASURES

Clinical indicator	Ages 18-29	Ages 30-39 Ages 40-49	Ages 50-64	Ages 65+						
Chlamydia screening	Sexually active members ages 24 and younger.	Members who are	e at increased risk.							
Colorectal cancer screening		at average risk oprevious adem predisposes to occult blood to colonoscopy depends on reci	omatous polyp(s), previous colore hem to a high risk of colorectal ca est, sigmoidoscopy, computed tor ) are subject to provider recomme	of have inflammatory bowel disease, ctal cancer, or a family history that neer. Screening procedures (fecal nography [CT] colonography, and endation. Frequency of screening parations for colonoscopy limited to						
Contraception	Food and Drug Administration-app an available generic alternative. If y	roved contraceptive methods, sterilization procedures, and patient educa our provider recommends a brand-name drug with an available generic, drug covered without cost sharing. See the cost-sharing exceptions form	your provider may submit an excep	tion request to have the brand-name						
Gonorrhea screening	Sexually active members ages 24 and younger.	Members who are	at increased risk.							
Fall prevention				Community-dwelling members ages 65 and older who are at increased risk for falls may receive exercise interventions to aid in fall prevention.						
Hepatitis B screening	Mernbers who are at increased risk									
Hepatitis C virus infection screening	Recommended one-time screening disease. Screenings as necessary	g for asymptomatic members ages 18-79 who are considered low risk foll ary for asymptomatic members who have not been diagnosed with liver o	owing clinical assessment and who disease but who are at increased ris	have not been diagnosed with liver						
Human immunodeficiency virus (HIV) infection prevention	Pre-ex	posure prophylaxis (PrEP) with effective antiretroviral therapy for member	ers who are at high risk of HIV acqu	uisition.*						
Human immunodeficiency virus (HIV) screening		Members ages 15-65 and/or sexually active members who are you	inger than 15 or older than 65.							
Lung cancer screening			and currently smoke or have quit	a 20 pack per year smoking history within the past 15 years may receive ening at a Center of Excellence.						
Osteoporosis screening		ng with bone density testing to prevent osteoporotic fractures in <b>postme</b> who are at increased risk of an osteoporotic fracture, as estimated by a c		One-time screening with bone density testing to prevent osteoporotic fractures in women 65 years and older.						
Prediabetes and type 2 diabetes screening		Screening in adults age	s 35 to 70 who are overweight or	obese.						
Screening for diabetes after pregnancy	Screening for members with a history of gestational diabetes mellitus who are not currently pregnant and who have not previously been diagnosed with type 2 diabetes mellitus. Initial testing should ideally occur within the first year postpartum and can be conducted as early as 4-6 weeks postpartum. Members who were not screened in the first year postpartum or those with a negative initial postpartum screening test result should be screened at least every three years for a minimum of 10 years after pregnancy. For members with a postpartum screening test result in the early postpartum period, testing should be repeated at least 6 months postpartum to confirm the diagnosis of diabetes, regardless of the initial test. Repeat testing is indicated for members who were screened with hemoglobin Alc in the first 6 months postpartum, regardless of the result.									
Statin use for the prevention of cardiovascular disease (CVD)				actors, and a calculated 10-year CVD						
Syphilis screening		Members who are at increased risk.								
Tobacco cessation medications <sup>1</sup>	Up	to 180 days of pharmacotherapy per year, as prescribed by a doctor, for r	nembers age 18 and older who sm	oke.*						

## Covered Preventive Services for Adults Ages 18 and Older (cont'd)

#### PREVENTIVE MEASURES

Clinical indicator	Ages 18-29 Ages 30-39 Ages 40-49 Ages 50-64 Ages 65+
Latent tuberculosis infection screening	Members who are at increased risk.
Urinary incontinence	Annually.

Member must have pharmacy benefits through UPMC Health Plan. Prescription required. Pharmacotherapy approved by the Food and Drug Administration and identified as effective for treating tobacco dependence in nonpregnant adults.

#### PREVENTIVE SERVICES FOR PREGNANCIES

PREVENTIVE SERVICES FOR PREGNANCIES	
Clinical indicator	and the control of th
Alcohol use screening	Expanded counseling and interventions for pregnant members.
Anxiety screening	Screening intervals based upon clinical judgment.
Aspirin use for the prevention of pre-eclampsia	Low dose aspirin (81 mg/day) for pregnant members who are at high risk for pre-eclampsia after 12 weeks of gestation.*
Bacteriuria screening	Screening for asymptomatic bacteriuria using urine culture in pregnant members.
Breastfeeding	Comprehensive support and counseling from trained providers, as well as access to breastfeeding supplies for pregnant and nursing members.
Chlamydia and gonorrhea screening	Pregnant members ages 24 and younger, or pregnant members 25 and older who are at increased risk.
Depression	Screen or refer pregnant and postpartum (less than one year) members for counseling
Diabetes screening	Members 24-28 weeks pregnant and at first prenatal visit for those at high risk of developing gestational diabetes.
Folic acid supplements (< 1 mg)	Members who are or may become pregnant.*
Healthy weight and weight gain in pregnancy: Behavioral counseling interventions	Behavioral counseling for interventions aimed at promoting healthy weight gain and preventing excess weight gain in pregnancy.
Hepatitis B virus infection screening	Screening for pregnant members at their first prenatal visit.
HIV screening	Screening for pregnant members.
Hypertensive disorders screening	Screening in pregnant members with blood pressure measurements throughout pregnancy.
Respiratory syncytial virus (RSV) immunization	Each pregnancy, seasonal administration between 32 and 36 weeks.
Rh(D) incompatibility screening	Screening for pregnant members at first prenatal visit and follow-up testing for pregnant members with increased risk.
Syphilis screening	Early screening for pregnant members.
Tdap	Each pregnancy, with timing of administration based on clinical recommendations.
Tobacco use screening	Screen pregnant members, advise to stop use (if applicable), and provide behavioral interventions for tobacco cessation.

<sup>\*</sup>Member must have pharmacy benefits through UPMC Health Plan. Prescription required. Preventive coverage of prescription drugs may be limited to generics. If a brand-name drug is not automatically considered preventive, a medical exception may be needed. If you have questions about preventive coverage of contraceptives or other prescription drugs, please call our Health Care Concierge team at the number on your member ID card.

#### **Recommended Immunization Schedule for Adults**

VACCINE▼ AGE GROUP ►	18-26 years	27-49 years	50-64 years ≥ 65 years									
COVID-19 <sup>6</sup>			The state of the s									
Haernophilus influenzae type b (Hib)	1 or 3 doses depending on indication											
Hepatitis A		2 or 3 doses depending on	vaccine									
Hepatitis B	2, 3, or 4 doses depa	ending on vaccine or condition	2, 3, or 4 doses depending on vaccine or condition for those 60 years and older									
Hurnan papillomavirus (HPV) (female and male)	2 or 3 doses depending on age at initial vaccination or condition	27 through 45 years	. OS years and order									
Influenza (flu shot)	MARCHAEL CONTRACTOR	Thromas Annually										
Measles, mumps, rubella (MMR)*	1 or 2 doses depending on clinical indication											
Meningococcal A, C, W, Y (MenACWY)*	1 or 2 doses depending on indication <sup>↑</sup>											
Meningococcal B (MenB) <sup>-4</sup>	2 or 3 doses depending on vaccine type and per indication*											
Мрох		2 doses, 28 days apa	rt									
Pneumococcal (PCV15, PCV20, PPSV23)		1 dose PCV15, followed by PPSV23 OR 1 dose PCV20	1 dose PCV15, followed by PPSV23 OR 1 dose PCV20									
Respiratory syncytial virus (RSV)	Seasonal administration during pregnancy. See Pr	reventive Services for Pregnancies section.	1 dose for those 60 years and older									
Tetanus, diphtheria, pertussis (Td/Tdap)	1 dose Tdap, th	en Td or Tdap booster every 10 yrs or for wound man	agement if greater than 5 years since last dose*									
Varicella (VAR)	2 doses (if born in 1	980 or later)	2 doses									
Zoster live (ZVL)			1 dose for those 60 years and older									
Zoster recombinant (RZV)	2 doses for immunocompr	omising conditions	2 doses									

For all persons in this category who meet the age requirements and who lack documentation of vaccination or have no evidence of previous infection, zoster vaccine recommended regardless of prior episode of zoster

Recommended if some other risk factor is present (e.g., on the basis of medical, occupational, lifestyle, or other indication)

Range of recommended ages for groups that may receive vaccine, subject to individual clinical decision making. May require prior authorization.

- COVID-19: Everyone ages 6 months or older should receive an updated COVID-19 vaccine to protect against COVID-19 whether or not they have ever previously been vaccinated with a COVID-19 vaccine. This takes effect as new vaccines are available.

  Special situations for Men ACWY:

  Anatomical or functional asplenia (including sickle cell disease), HIV infection, persistent complement component deficiency, complement inhibitor (e.g., eculizumab, ravulizumab) use: Two-dose series MenACWY (MenQuadfi, Menveo) at least eight weeks apart and revaccinate
- every five years if risk remains.

  Travel in countries with hyperendemic or epidemic meningococcal disease, microbiologists routinely exposed to Neisseria meningitidis: One dose MenACWY (MenQuadfi, Menveo) and revaccinate every five years if risk remains.

  First-year college students who live in residential housing (if not previously vaccinated at age 16 years or older) and military recruits: One dose MenACWY (MenQuadfi, Menveo)
- Shared clinical decision making for MenB:
- Adolescents and young adults ages 16-23 years (ages 16-18 years preferred) not at increased risk for meningococcal disease: Based on shared clinical decision making, two-dose series Men8-4C at least one month apart, or two-dose series Men8-FHbp at 0 and 6 months (if dose two was administered less than six months after dose one, administer dose three at least four months after dose two), Men8-4C and Men8-FHbp are not interchangeable (use same product for all doses in series) Special situations for MenB:
- Anatomical or functional asplenia (including sickle cell disease), persistent complement component deficiency, complement inhibitor (e.g., eculizumab, ravulizumab) use, microbiologists routinely exposed to Neisseria meningitidis: Two-dose primary series Men8-4C (Bexsero) at least one month apart, or three-dose primary series Men8-FHbp (Trumenba) at 0, 1–2, and 6 months (if dose two was administered at least six months after dose one, dose three is not needed), Men8-4C and Men8-FHbp are not interchangeable (use same product for all doses in series), one dose Men8 booster one year after primary series and revaccinate every two to three years if risk remains

  Pregnancy: Delay Men8 until after pregnancy unless at Increased risk and vaccination benefits outweigh potential risks.

\*Meningococcal A, C, W, Y (MenACWY-TT)/Meningococcal B (MenB-FHbp) may be used when both MenACWY and MenB are indicated at the same visit for 1) healthy persons aged 16-23 years (routine schedule) when shared clinical decision-making favors administration of MenB vaccine and 2) persons aged \$10 years who are at increased risk for meningococcal disease (e.g., because of persistent complement deficiencies, complement inhibitor use, or functional or anatomic asplenia).

## **Covered Preventive Services for Children**

#### **SCREENINGS**

Services*	并清付地站		<b>与国际部分</b> 。	为"行"的特殊。	Military of	Infancy	Charles Charles			为为"大"。"你们					
Services	Birth to 1 mo	2-3 mos	4-5 mos	6-8 mos	9-11 mos	12 mos	15 mos	18 mos	24 mos	30 mos					
Anemia screening						×									
Autism screening								×	×						
Behavioral assessments	×	×	×	×	×	×	×	×	×	×					
Body mass index (BMI) measurements									×	×					
Critical congenital heart defect	×					WEST PROPERTY.									
Developmental screening					×			×		x					
Developmental surveillance	×	×	×	x		×	×		×						
Fluoride supplements		For children ages 6 months through 16 years whose water supply is deficient in fluoride."													
Fluoride varnish to primary teeth				All children a	nnually beginning a	t first primary tooth	eruption to 5 year	·s.							
Gonorrhea (preventive medication)	×														
Hearing	Once at birt before end o														
Hearing tests	×	×				May be complet	ed up to 30 month:	S.							
Hepatitis B (HBV)				Children a	at increased risk as	determined by clin	ical assessment.								
Lead screening						×			×	Ages 30 months to 5 years and as required by local or state law.					
Newborn bilirubin	×														
Newborn blood (including RUSP)	×	×													
Skin cancer behavioral counseling							Children with fair s	kin.							
Tuberculosis testing				As recommende	d by doctor and ba	sed on history and/	or signs and sympte	oms.							
Vision				Asse	ss through observa	tion or health histo	ry/physical.								
Well-child, including height and weight	×	×	×	×	×	×	×	×	×	×					

<sup>\*</sup>Member must have pharmacy benefits through UPMC Health Plan. Prescription required. Preventive coverage of prescription drugs may be limited to generics. If a brand-name drug is not automatically considered preventive, a medical exception may be needed. If you have questions about preventive coverage of contraceptives or other prescription drugs, please call our Health Care Concierge team at the number on your member ID card.

#### Covered Preventive Services for Children (cont'd)

### SCREENINGS

Services	Television of the second	以前的情報表現	1000000		等的形式以	306 on a	<b>多的数数数数</b>	THE RESERVE OF THE PERSON NAMED IN	lhood 🧼		精神疾病			Mark and	La libraria	Charge
	3 yrs	4 yrs	5 yrs	6 yrs	7 yrs	8 yrs	9 yrs	10 yrs	11 yrs	12 yrs	13 yrs	14 yrs	15 yrs	16 yrs	17 yrs	18 yrs
Behavioral/Social/Emotional screening	-	Annually.														
Blood pressure									ually.							
Body mass index (BMI) measurements	-	т	T			1		Ann	ually.							
Cholesterol dyslipidemia screening		X X													×	
Depression, anxiety, and suicide risk		Screen/Counsel for major depressive disorder (MDD), anxiety and suicide riskin adolescents through age 21.													21.	
Developmental surveillance		Service Uni						Ann	ually							
Fluoride supplements				For chil	dren ages 6	months thro	ough 16 year	s whose wat	er supply is	deficient in	fluoride.*					T
Fluoride varnish to primary teeth						All children	annually be	ginning at fir	rst primary t	ooth erupti	on to 5 years					
Hearing		×	×	×		×		×	×					X Or 18-		Once b/ 18-21 yrs
Hepatitis B (HBV)						Childre	en at increas	ed risk as de	termined by	clinical ass	essment.					
Hepatitis C																×
Human immunodeficiency virus (HIV)**									Children		l risk as dete ssessment.	rmined by	includ participa	ng those wh te in injection other STIs, s	risk of HIV in o are sexually n drug use, or hould be test sed annually.	y active, r are being ted for HIV
Lead screening	Ages 30 m required	onths to 5 y by local or	rears and as state law.													
Obesity screening									Annua	lly though 1	8 years.					
Screen/Counsel for alcohol and drug use, sexually transmitted infections, tobacco use, and intimate partner violence as needed												Ann	ually.			
Sickle cell test							As indica	ated by histo	ry and/or sy	mptoms.						
Skin cancer behavioral counseling	1							Children wi	ith fair skin.							
Sudden cardiac arrest/death				WEEKLER !		Treation.		THE PER	1000	Α	nnually or a	clinically a	poropriate t	hrough age	21.	DECEMBED.
Tuberculosis testing			-		As	recommen	ded by docto	or and based	on history a					00-		
Vision	All child	dren ages 3- n amblyopia	5 should screening.							Annually.						
Well-child, including height and weight								Annı	ually.							

<sup>\*</sup>Member must have pharmacy benefits through UPMC Health Plan. Prescription required. Preventive coverage of prescription drugs may be limited to generics. If a brand-name drug is not automatically considered preventive, a medical exception may be needed. If you have questions about preventive coverage of contraceptives or other prescription drugs, please call our Health Care Concierge team at the number on your member ID card.

<sup>\*\*</sup>The United States Preventive Services Task Force suggests that clinicians weigh all these factors when considering PrEP use in adolescents at high risk of HIV acquisition (jamanetwork.com/journals/jama/fullarticle/2735509).

#### **Recommended Immunization Schedule for Children**

Vaccine	Birth	1 mo	2 mos	4 mos	6 mos	9 mos	/ 12 mos	15 mos //	/18 mas	19-23 mos	. 2-3 yrs	4-6 yrs	7-10 yrs	11-12 yrs	13-15 yrs	16-	18 yrs
COVID-19 <sup>4</sup>						10 8000											16.18
Dengue (DEN4CYD; 9-16 yrs)													3	dose series; endemic a		in	
Diphtheria, tetanus, and acellular pertussis (DTaP: < 7 yrs)			1st dose	2nd dose	3rd dose			4th	dose	1971		5th dose	, , , , , , , , , , , , , , , , , , ,	1		T	
Haemophilus influenzae type b (Hib)			1st dose	2nd dose			3rd or	4th dose									
Hepatitis A (HepA)								2-dose	series¥		A. Hus	White St	Mark 1	S CONTRACT	Charles I	17 12	<b>H</b>
Hepatitis B (HepB)	1st dose	2nd	dose	11/1/16			3rd dose	N.C.				data da		Y ( ) ( )	el arrangement		
Human papillomavirus (HPV)												***************************************		2-dose series			
Inactivated poliovirus (IPV) (< 18 yrs)			1st dose	2nd dose			3rd dose					4th dose					
Influenza (flu shot), (IIV) 2 doses for some											Annually						
Measles, mumps, rubella (MMR)						100	1st	dose		Sec. 17	16 (4) (2) (4)	2nd dose	Catalon	Padrate.	77.55.70		NW.
Meningococcal (MenACWY-TT ≥ 2years, MenACWY-CRM ≥ 2 mos)														1st dose		2nd dose	
Meningococcal B <sup>#</sup>																1555	
Мрох																	2 dose 28 day apart
Pneumococcal conjugate (PCV15, PCV20)			1st dose	2nd dose	3rd dose		4th	dose									apart
Pneumococcal polysaccharide (PPSV23)							*****										
Respiratory syncytial virus	1 dose for i	nfants born	during or e	ntering their	first RSV se	ason								T	T	T	-
Rotavirus (RV) RV1 (2-dose series); RV5 (3-dose series)			1st dose	2nd dose													
Tetanus, diphtheria, and acellular pertussis (Tdap: ≥ 7 yrs)														Tdap			
Varicella (VAR)							elle lava	dose	er diversity (SIA	and the state of the		2nd dose	NAME OF TAXABLE PARTY.				

"Hepatitis A (HepA): Two doses should be administered six months apart. Recommended minimum age for first dose is 12 months.

"Dengue Vaccine: Age 9-16 years living in dengue endemic areas AND have laboratory confirmation of previous dengue infection. Three doses should be administered 6 months apart at 0, 6, and 12 months.

"OVID-19: Everyone ages 6 months or older should receive an updated COVID-19 vaccine to protect against COVID-19 whether or not they have ever previously been vaccinated with a COVID-19 vaccine. This takes effect as new vaccines are available.

\*Meningococcal B: For more information on special situations and shared clinical decision making, see the bottom of page 4.

Copyright 2025 UPMC Health Plan Inc. All rights reserved. PREV SVCS QUIDE 2025 V1 25CQ NOS424950 (MQ) 7/25/25 PDF

UPMC HEALTH PLAN upmchealthplan com 

# **UPMC HEALTH PLAN**

## Prior authorization form

## Cost-Sharing Exceptions for Contraceptives - Commercial Marketplace and CHIP

**Phone:** 1-800-979-UPMC (8762) **Fax:** 412-454-7722

Providers should complete this form and submit via fax, or submit a request online at upmc.promptpa.com.

B ()									
Patient name:			Prescriber name:						
UPMC member ID#:		<b></b>	Prescriber specialty:						
Date of birth:		Age:	Office contact:						
Drug name and strength:			NPI:						
☐ Brand ☐ Generic			Fax:	Phone:					
Frequency:	Quantity disp (units):	ensed	1	oing, did the member show on therapy? ☐ Yes ☐ No ☐ N/A					
Generic-equivalent dru	ıgs will be subst	ituted for brand	l-name drugs unless yo	u specifically indicate otherwise.					
Place of administration (if bi ☐ Physician's office ☐ Ho	lling medically) spital/Facility	): □ Patient ho	me 🗖 Other						
Please provide hospital/facil medically):  Name: Phone: Address:			Please indicate how medication will be billed:  ☐ Billed directly by the provider via JCODE  JCODE: ☐ Billed by a pharmacy and delivered to the provider ☐ Billed by a pharmacy and delivered to the patient						
				ed review will be considered when a other person(s) in serious jeopardy.					
Q1. Is this request for new or New	continuation o	of therapy?  ☐ Continu	ation						
Q2. Please provide start date	of medication.								
Q3. Please provide the mem	ber's diagnosis	or medical con	dition.						
Q4. Please provide any medi therapy, and reason for o			t the member's condit	ion, including dosage, dates of					
Q5. Is this contraceptive met Yes	hod/medication	n medically nec	essary for the membe	?	_				
Q6. Please provide the clinic for the member.	al rationale for v	why this contra	ceptive method/media	ation is medically necessary					